Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature

Edgardo S. Santos, Leopoldo R. Arosemena, Luis E. Raez, Christopher O'Brien, Arie Regev

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe a case of a 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant autoimmune hepatitis (AIH), both non-responsive to steroids. She was subsequently treated with rituximab, which resulted in a rapid increase in her platelet count and an unexpected normalization of her hepatic biochemical tests. Both her platelet count and her hepatic biochemical tests remained normal for over 5 months. In this case, rituximab showed an impressive clinical response for the treatment of AIH, and it may be considered as an alternative treatment in patients who do not respond to corticosteroid therapy. Prospective randomized studies in AIH are needed to validate this observation.

Original languageEnglish (US)
Pages (from-to)625-629
Number of pages5
JournalLiver International
Volume26
Issue number5
DOIs
StatePublished - Jun 1 2006

Keywords

  • Autoimmune hepatitis
  • Idiopathic thrombocytopenic purpura
  • Monoclonal antibody
  • Rituximab

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature'. Together they form a unique fingerprint.

  • Cite this